Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

56
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
56
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

660
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
660
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

642
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
642

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Low-Density Lipoprotein Cholesterol and Dementia Risk: Integrating Mendelian Randomization and Target Trial Emulation Within the Heart-Brain Axis.

medRxiv : the preprint server for health sciences·2026
Same author

CKM Multimorbidity Burden and Phenotype Differentially Influence Cardiovascular and Renal Risk in Advanced CKD.

Cardiorenal medicine·2026
Same author

Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.

Kidney international reports·2026
Same author

Metabolic syndrome and kidney dysfunction: emerging molecular and cellular mechanisms at the metabolic-renal interface.

Frontiers in endocrinology·2026
Same author

Updated BJP guidelines for transparent and rigorous natural product research.

British journal of pharmacology·2026
Same author

Automating the quality monitoring of a hospital discharge summary improvement project utilising large language models.

NPJ digital medicine·2026
Same journal

Re-thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics.

British journal of pharmacology·2026
Same journal

Tangeretin ameliorates sepsis-induced neurocognitive impairment in adult male mice by suppressing Akt-driven glycolytic reprogramming and neuroinflammation.

British journal of pharmacology·2026
Same journal

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having 'bifunctional' bronchodilator and anti-inflammatory activity.

British journal of pharmacology·2026
Same journal

Glucagon-like peptide-1 improves vascular endothelial dysfunction in hypertensive mice via CREB-driven transcriptional regulation of long non-coding RNA 155383.

British journal of pharmacology·2026
Same journal

The chemokine receptor-like fourth extracellular loop of the apelin receptor differentially regulates apelin and elabela binding and signalling.

British journal of pharmacology·2026
Same journal

Peripheral targets for neuropathic pain.

British journal of pharmacology·2026
查看所有相关文章

相关实验视频

Updated: Sep 19, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K

推进抗高血压药物的开发.

Fay Pu1, Yanrong Liu2, Fozia Zahir Ahmed3

  • 1Intensive care units, University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, UK.

British journal of pharmacology
|June 3, 2025
PubMed
概括
此摘要是机器生成的。

创新的高血压治疗方法,如阿尔多氨酸合成酶抑制剂和基于RNA的疗法,可以改善血压控制和心脏和脏的益处. 这些新的策略针对潜在的机制来克服耐药性并提高患者的治疗结果.

关键词:
末端素受体对抗剂 末端素受体对抗剂这种高血压,高血压.矿物质皮质类受体对抗剂.

更多相关视频

Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.6K
Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.3K

相关实验视频

Last Updated: Sep 19, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.6K
Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
10:09

Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound

Published on: August 4, 2022

3.3K

科学领域:

  • 心血管医学 心血管医学
  • 药理学 药理学是指药理学的学科.
  • 腎臟病學 (nephrology) 是一種醫學專業.

背景情况:

  • 高血压影响全球超过10亿人,导致严重的心血管问题.
  • 目前的治疗方法面临着诸如耐药性,副作用和不良坚持等挑战,阻碍了最佳的血压控制.

研究的目的:

  • 审查用于管理高血压的创新治疗策略.
  • 探索解决治疗耐药性,不良影响和坚持挑战的新方法.

主要方法:

  • 对新出现的药理学药物的综述,包括阿尔多氨酸合成酶抑制剂,矿物质皮质类受体对抗剂和内甲素受体对抗剂.
  • 分析新的治疗方式,如基于RNA的疗法 (例如,zilebesiran),AT2受体激动剂,ACE2激活剂和NAD+增强化合物.
  • 讨论支持策略,如肠道微生物组调节和固定剂量组合药丸.

主要成果:

  • 阿尔多氨酸合成酶抑制剂和非类固醇矿物质皮质类受体对抗剂表明改善了血压控制,增强了心脏和脏的保护,降低了高血症的风险.
  • 内甲素受体对抗剂通过向血管收缩,显示出治疗耐药高血压的潜力.
  • 基于RNA的疗法,如zilebesiran,通过通过低频剂量抑制血管素原来持续降低血压.

结论:

  • 新兴疗法针对特定的病理生理路径,以精确的方法来管理高血压.
  • 新的策略有望改善血压控制,减少全球高血压负担,并改善患者的治疗结果.
  • 未来的研究和这些创新的临床应用对于推进高血压护理至关重要.